20/20NOW INCORPORATES RETINAL AI INTO ITS OCULAR TELEHEALTH EXAM TO PROVIDE EARLY DIAGNOSIS OF DIABETIC RETINOPATHY

September 13, 2018 —

NEW YORK, N.Y. 20/20NOW, the pioneer and innovator of Ocular Telehealth, has announced it’s now using Artificial Intelligence, to enable the early detection of diabetic retinopathy. Through the use of FDA approved equipment and software during 20/20NOW’s comprehensive telehealth exam, scientific algorithms are used to immediately enhance retinal images to identify lesions in the retina. Diabetic retinopathy if untreated, results in vision loss and ultimately blindness. These lesions are typically undetectable to the human eye. Identifying diabetic retinopathy in its early stages, when it’s most treatable, is critical to preventing blindness and lowering health care costs.

According to the world health organization, the world is experiencing a growing epidemic of diabetes. In the U.S. alone, 1 out of 11 Americans have been diagnosed with the disease, but more concerning, 1 out of 3 Americans have pre-diabetes and most of them don’t know it. Diabetic retinopathy is a major cause of blindness in the United States, causing 12,000–24,000 new cases each year. However, only about half of persons with type 2 diabetes on average received an annual eye examination. A number of factors suggest that emerging telemedicine screenings with appropriate referral represents a cost-effective solution to increase access to eye care. The combination of AI and retinal screenings within telehealth eye exams can now provide both increased access to care and earlier detection of diabetic retinopathy to prevent unnecessary vision loss.

Telehealth industry veteran and 20/20NOW CEO, Chuck Scott, shared “Our mission at 20/20NOW is to expand access to comprehensive eye exams while also improving the standard of care, at a lower cost to our patients. Through the use of cutting-edge technology and artificial intelligence, our Ocular Telehealth eye exams represent a cost-effective tool to help solve one of the most pressing health care issue in our country today.”

Scott shared further, “The opportunity exists to combine the use of AI and Ocular Telehealth to cost effectively screen and detect other critical health diseases beyond diabetic retinopathy. We believe there will be a vast array of ocular diseases that can be detected through AI and retinal screenings in the future. We look forward to partnering with leading technology companies and health providers in the future to bring these capabilities to market.”

About 20/20NOW
20/20NOW is the pioneer and innovator of Ocular Telehealth. Using state-of-the-art technology, proprietary software and patented exam processes, 20/20NOW provides comprehensive eye exams, including eye health screenings, via telehealth. The company’s telehealth model allows eye care professionals and optical retailers to provide their patients with increased access to high quality eye exams at a lower cost.

For more information, contact:

Greg Lechner
Marketing and Communications Director
20/20NOW
glechner@for2020now.com
www.for2020now.com